{"id":680510,"date":"2023-12-08T18:38:01","date_gmt":"2023-12-08T18:38:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=680510"},"modified":"2023-12-08T18:38:01","modified_gmt":"2023-12-08T18:38:01","slug":"vaccine-adjuvants-market-worth-12-billion-marketsandmarkets","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/vaccine-adjuvants-market-worth-12-billion-marketsandmarkets_680510.html","title":{"rendered":"Vaccine Adjuvants Market worth $1.2 billion | MarketsandMarkets"},"content":{"rendered":"
\n
\"Vaccine<\/a><\/div>\n
\n
In May 2023 Croda International Plc (UK) entered into a partnership with Amyris (US) and Botanical Solutions Inc. (BSI) firstly for biotechnology-derived squalene and secondly with BSI for develop a sustainable QS-21 vaccine adjuvant moving towards plant tissue culture-derived approach rather than traditional method of extracting QS-21 from soap bark trees.<\/div>\n<\/div>\n<\/div>\n
The vaccine adjuvants industry is poised for remarkable growth in the near future, as the global demand for effective vaccines continues to surge.<\/div>\n

Vaccine Adjuvants Market<\/a><\/strong> in terms of revenue was estimated to be worth $0.8 billion in 2023 and is poised to reach $1.2 billion by 2028, growing at a CAGR of 6.9 % from 2023 to 2028 according to a new report by MarketsandMarkets™. The global vaccine adjuvants market is expected to grow at a CAGR of 6.9% during the forecast period. The major factors driving the growth of the market are collaborations & partnerships among market players for vaccine adjuvants development, increasing focus on immunization programs and rise in number of vaccine approvals in last 2-3 years.<\/p>\n

The adjuvant emulsions segment is expected to have the dominant share of the vaccine adjuvants market in 2022:<\/strong><\/p>\n

Based on product, the global vaccine adjuvants market is segmented into adjuvant emulsions, pathogen components, saponin-based adjuvants, particulate adjuvants, and other adjuvants. In 2022, the adjuvant emulsions segment accounted for largest share of the vaccine adjuvants market. Increased use of adjuvant emulsions in the vaccine production is serving as driving factor for the growth of the adjuvant emulsions segment during the forecast period.<\/p>\n

The infectious disease segment accounted for the largest share of the disease type segment in the vaccine adjuvants market in 2022.<\/strong><\/p>\n

The infectious diseases segment is the fastest growing segment and accounted for the largest share of the market in 2022. The large share of this segment can be attributed to rising demand for novel adjuvanted vaccines for infectious diseases. Rising focus on development of plant-based adjuvants is further likely to have positive impact on the segmental growth.<\/p>\n

The Asia Pacific region is the fastest-growing region of the vaccine adjuvants market in 2022.<\/strong><\/p>\n

The Asia Pacific is estimated to be the fastest-growing segment of the market. The growth of the vaccine adjuvants markets on the region is driven by rising emphasis on strategic initiatives such as partnerships, collaborations & expansion and increased adoption of adjuvanted vaccine among the patent population.<\/p>\n

 <\/p>\n

Vaccine Adjuvants Market Dynamics:<\/strong><\/p>\n

Drivers:<\/strong><\/p>\n

    \n
  1. Rising prevalence of infectious diseases<\/li>\n<\/ol>\n

    Restraints:<\/strong><\/p>\n

      \n
    1. Side Effects and High Toxicity of Adjuvants<\/li>\n<\/ol>\n

      Opportunities:<\/strong><\/p>\n

        \n
      1. Rising funding for vaccines and infectious disease research activities<\/li>\n<\/ol>\n

        Challenges:<\/strong><\/p>\n

          \n
        1. Concerns regarding animal-sourced vaccine adjuvants and limitations on shark fishing<\/li>\n<\/ol>\n

          Key Market Players:<\/strong><\/p>\n

          The vaccine adjuvants market is competitive, with a small number of players competing for market shares. Dynavax Technologies (US), GSK plc (UK), Croda International plc (UK), SEPPIC (France), Novavax (US), SPI Pharma (Associated British Foods plc) (UK), Agenus Inc. (US), Phibro Animal Health Corporation (US), Aurorium (Vertellus) (US), Merck KGaA (Germany) are some of the leading players in this market. Most companies in the market focus on organic and inorganic growth strategies, such as product launches, expansions, acquisitions, partnerships, agreements, and collaborations, to increase their product offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.<\/p>\n

          Inquire Before Buying @  https:\/\/www.marketsandmarkets.com\/Enquiry_Before_BuyingNew.asp?id=152603894<\/a><\/strong><\/p>\n

          Media Contact<\/span>
          Company Name:<\/strong>           MarketsandMarkets\u2122 Research Private Ltd.<\/a>
          Contact Person:<\/strong> Mr. Aashish Mehra
          Email:<\/strong>           Send Email<\/a>
          Phone:<\/strong> 18886006441
          Address:<\/strong>630 Dundee Road Suite 430
          City:<\/strong> Northbrook
          State:<\/strong> IL 60062
          Country:<\/strong> United States
          Website:<\/strong>           https:\/\/www.marketsandmarkets.com\/Market-Reports\/vaccine-adjuvants-market-152603894.html<\/a><\/p>\n

          <\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

          In May 2023 Croda International Plc (UK) entered into a partnership with Amyris (US) and Botanical Solutions Inc. (BSI) firstly for biotechnology-derived squalene and secondly with BSI for develop a sustainable QS-21 vaccine adjuvant moving towards plant tissue culture-derived approach … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,403,404,416],"tags":[],"class_list":["post-680510","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/680510","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=680510"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/680510\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=680510"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=680510"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=680510"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}